OneOme, the Mayo Clinic spinoff known for the RightMed pharmacogenomics test, announced a sudden closure of operations citing financial challenges. The Minneapolis‑based company will stop accepting new orders by Nov. 4 and will process samples received by Nov. 7, leaving clinical labs and health systems that relied on OneOme scrambling to secure alternative PGx testing arrangements. Clinicians and precision‑medicine programs flagged the timing as disruptive because recent guideline updates—such as mandatory DPYD testing before capecitabine use—have increased demand for PGx services. Several health systems that partnered with OneOme are reportedly moving to in‑house testing or new vendors. The shutdown underscores fragility in clinical genomics service providers and highlights risks to compliance and patient safety when a specialized provider exits the market unexpectedly.